AI-generated content for informational purposes only. Not financial advice. Always do your own research.

About

Medtronic is the world largest medical device company, manufacturing products spanning cardiac and vascular therapies, surgical robotics, spinal implants, diabetes management, and neuroscience solutions. The company serves hospitals and clinics in over 150 countries and has a pipeline of innovative devices aimed at improving patient outcomes. Medtronic is a core holding for healthcare-focused investors seeking dividend income backed by essential, recession-resistant medical spending.

Aging Population Stocks

Medtronic's comprehensive medical device portfolio spanning cardiac, surgical, spinal, and diabetes therapies positions it as a primary beneficiary of healthcare demand from aging populations.

Blue Chip Stocks

As the global leader in medical devices with operations in over 150 countries and an unmatched breadth of therapeutic offerings, Medtronic carries the scale, market position, and financial stability that define a healthcare blue chip.

Dividend Aristocrat Stocks

Medtronic is the world's largest medical device company with a decades-long dividend growth track record, manufacturing products across cardiac, surgical robotics, spinal, and diabetes care.

Dividend Stocks

Medtronic has increased its dividend for over 45 consecutive years, powered by the recurring revenue streams from its installed base of implantable devices and the essential nature of the medical procedures its products support.

Healthcare Stocks

Medtronic is the world's largest pure-play medical device company, with leadership positions in cardiac rhythm management, surgical robotics, spinal therapies, and diabetes care that make it a foundational healthcare sector holding.

Key Financials MDT

Price $99.49
Change (1D) -1.38%
Change (30D) +3.57%
Change (60D) +3.33%
Change (90D) +1.08%
Change (180D) +22.46%
Change (1Y) +8.91%
Change (5Y) -15.60%
P/E Ratio 30.24
EPS (TTM) $3.29
52-Week Range $79.55 โ€” $106.33
50-Day MA $99.58
Volume 10.35M

Data updated Feb 15 ยท Source: Twelve Data

4.3 2 reviews

AI Reviews

๐Ÿค–
4.0 /5

Medtronic is the world's largest pure-play medical device company, with dominant positions in cardiac rhythm management, spinal surgery, diabetes care, and surgical robotics. Its diversified portfolio is exceptionally well-positioned to benefit from aging demographics globally. The company has raised its dividend for 47 consecutive years, cementing its Dividend Aristocrat status, with a current yield around 3.4%"attractive for income investors.

However, the investment case has notable concerns. The 5-year return of -15.6% reflects persistent execution challenges, margin pressure, and slower-than-expected growth in key segments. At a P/E of 30.24 with EPS of just $3.29, the valuation appears stretched relative to recent earnings power. The stock's recovery from its 52-week low of $79.55 (+25%) suggests renewed optimism around its Hugo surgical robot and pipeline catalysts, but sustained earnings acceleration is needed to justify the multiple.

Bull case: demographic tailwinds, improving pipeline execution, and reliable dividend growth. Bear case: premium valuation, competitive threats from smaller innovators, and a track record of underwhelming organic growth. Medtronic remains a solid defensive holding but needs to prove it can reignite top-line momentum.

Category Ratings

Aging Population Stocks
4.5
Blue Chip Stocks
3.8
Dividend Aristocrat Stocks
4.3
Dividend Stocks
3.9
Healthcare Stocks
3.7
Feb 15, 2026
AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more
๐Ÿค–
4.6 /5

Medtronic (MDT) continues to assert itself as a global leader in medical technology, offering a diversified portfolio across cardiovascular, neuroscience, and surgical robotics. As a Dividend Aristocrat, MDT is a staple for income-focused portfolios, providing reliable cash flow and a history of annual raises that appeals to conservative investors.

Currently trading near $101, the stock sits close to its 52-week high of $106.33, reflecting positive momentum above its 50-day moving average. However, with a P/E ratio of 30.72, the valuation appears somewhat stretched relative to historical norms, suggesting that future growth from innovations like the Hugo RAS system is already priced in. While the company benefits from significant long-term demographic tailwinds, investors should be mindful of competitive pressures and foreign exchange headwinds. Overall, Medtronic offers blue-chip stability, though value-oriented investors might wait for a pullback before initiating new positions.

Category Ratings

Blue Chip Stocks
4.6
Dividend Stocks
4.7
Healthcare Stocks
4.4
Feb 12, 2026
AI-Generated Review Generated via Google API. This is an automated evaluation, not a consumer review. Learn more